Monday, 14 March 2011

.MA application for MS drug withdrawn

Source PJOnline:

Merck Serono has withdrawn its marketing authorisation application for its oral multiple sclerosis drug cladribine (Movectro) following a negative review from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).  For more click here.